by Portfolio Grader | February 14, 2014 8:15 am
The grades of eight pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Forest Laboratories, Inc. (FRX) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Forest Laboratories develops, manufactures, and sells both branded and generic forms of ethical products which require a physician’s prescription. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, Earnings Revisions and Earnings Surprise, FRX also gets A’s. For more information, get Portfolio Grader’s complete analysis of FRX stock.
The rating of Merck & Co., Inc. (MRK) moves up this week, rising from a B to an A. Merck is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. For more information, get Portfolio Grader’s complete analysis of MRK stock.
Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Teva Pharmaceutical Industries is engaged in the provision of pharmaceutical services. For more information, get Portfolio Grader’s complete analysis of TEVA stock.
Watson Pharmaceuticals (WPI) is seeing ratings go up from a B last week to an A this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Flamel Technologies SA Sponsored ADR’s (FLML) ratings are looking better this week, moving up to an A from last week’s B. Flamel Technologies develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. For more information, get Portfolio Grader’s complete analysis of FLML stock.
Akorn, Inc. (AKRX) shows solid improvement this week. The company’s rating rises from a B to an A. Akorn engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. For more information, get Portfolio Grader’s complete analysis of AKRX stock.
Nektar Therapeutics (NKTR) gets a higher grade this week, advancing from a C last week to a B. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. For more information, get Portfolio Grader’s complete analysis of NKTR stock.
AcelRx Pharmaceuticals, Inc. (ACRX) boosts its rating from a C to a B this week. AcelRx focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. For more information, get Portfolio Grader’s complete analysis of ACRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2014/02/8-pharmaceutical-stocks-to-buy-now-frx-mrk-teva-2/
Short URL: http://invstplc.com/1gDzEdT
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.